Ardent Health Partners, Inc. (ARDT) AI Stock Analysis

• Market Cap: $1.84B
• Dividend Yield: N/A
• Average Volume (3M): 373.60K
• Price to Earnings (P/E): 7.2
• Beta (1Y): 0.51
• Revenue Growth: 10.03%
• EPS Growth: 197.26%
• Country: US
• Employees: 19,200
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Care Facilities
• EPS (TTM): 0.52
• Shares Outstanding: 143,106,450
• 10 Day Avg. Volume: 257,251
• 30 Day Avg. Volume: 373,602
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 2.20
• Enterprise Value/Revenue: 0.65
• Enterprise Value/Gross Profit: 1.07
• Enterprise Value/Ebitda: 6.58
• 1Y Price Target: $17.75
• Price Target Upside: 34.88% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

• Rating: 72 Outperform
• Price Target: $14.00 ▲(6.38% Upside)

Ardent Health Partners, Inc. scores well due to strong financial performance and attractive valuation. The earnings call provided positive insights into growth and operational improvements, despite some challenges. Technical analysis indicates moderate bullish momentum, supporting the overall positive outlook.

Positive Factors

Earnings

ARDT reported 2Q earnings well ahead of estimates, with the extent of the beat largely contingent on NM DPP program approval, which provided a significant EBITDA benefit.

Financial Performance

EBITDA grew nearly 40%, indicating strong financial performance.

Negative Factors

Financial Outlook

The company is moving from a period of EBITDA growth tailwinds to headwinds, reflecting a meaningful shift in financial outlook.

Medicaid and Exchange Cuts

Increasing headwinds from cuts to Medicaid and Accountable Care Act (ACA) exchanges are expected to lower volume growth and increase bad debt.

Regulatory Risks

ARDT should trade at a discount to publicly traded hospital peers due to its smaller scale, lower-margin profile, greater execution risk in ambulatory, and potential regulatory risks.

Ardent Health Partners, Inc. Business Overview & Revenue Model

Company Description

Ardent Health Partners, LLC owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, LLC is a subsidiary of EGI-AM Investments, L.L.C.

How the Company Makes Money

Ardent Health Partners generates revenue primarily through the provision of healthcare services, which include inpatient and outpatient care, surgical services, emergency services, and rehabilitation services. The company's revenue model is largely based on reimbursements from government programs such as Medicare and Medicaid, as well as private insurance payers. Key revenue streams include patient services revenue, which accounts for the majority of its income, and ancillary services like laboratory and imaging services, which provide additional financial support. Ardent Health also engages in strategic partnerships with other healthcare organizations and participates in value-based care initiatives that can lead to shared savings and improved reimbursement rates. These factors, combined with a focus on operational efficiency and patient satisfaction, contribute to the company's overall financial performance.

Ardent Health Partners, Inc. Financial Statement Overview

Summary

Ardent Health Partners, Inc. exhibits strong revenue growth and improved profitability, supported by a stable balance sheet and robust cash flow generation. Effective cost management and shareholder returns are evident, though there are areas for improvement in operational efficiency and liquidity management. The reliance on debt financing poses a potential risk, but the company maintains a solid financial position in the medical care facilities industry.

Income Statement

Ardent Health Partners, Inc. has shown strong revenue growth with a 10.29% increase from 2023 to 2024. The gross profit margin is robust at 57.51% for 2024, indicating effective cost management. The net profit margin improved significantly to 3.53% in 2024 from 0.93% in 2023, reflecting enhanced profitability. However, the EBIT and EBITDA margins, at 6.80% and 9.32% respectively, suggest room for improvement in operational efficiency.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 1.50, indicating a balanced approach to leveraging. Return on equity improved to 13.83% in 2024, showcasing effective use of shareholder funds. The equity ratio stands at 30.69%, which is reasonable but suggests a reliance on debt financing. Overall, the balance sheet reflects stability with potential risks from leverage.

Cash Flow

Ardent Health Partners, Inc. has demonstrated a positive free cash flow growth rate of 51.26% from 2023 to 2024, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 1.50, suggesting efficient cash conversion. However, the free cash flow to net income ratio is 0.61, indicating that not all net income is translating into free cash flow, which could be a concern for liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2018	Dec 2017
Income Statement
Total Revenue	6.20B	5.97B	5.41B	5.13B	4.16B	3.00B
Gross Profit	3.79B	3.43B	5.27B	4.17B	4.16B	3.00B
EBITDA	615.44M	555.92M	350.00M	531.70M	281.84M	230.91M
Net Income	254.86M	210.34M	50.29M	188.91M	-143.02M	-35.65M
Balance Sheet
Total Assets	5.03B	4.96B	4.73B	4.86B	2.75B	2.37B
Cash, Cash Equivalents and Short-Term Investments	540.63M	556.78M	437.58M	456.12M	59.66M	71.96M
Total Debt	2.27B	2.28B	2.40B	2.39B	1.26B	952.69M
Total Liabilities	3.38B	3.43B	3.65B	3.81B	2.03B	1.61B
Stockholders Equity	1.25B	1.13B	670.90M	639.05M	331.64M	377.72M
Cash Flow
Free Cash Flow	108.13M	127.52M	84.29M	-189.47M	-1.07M	-2.06M
Operating Cash Flow	301.98M	315.03M	221.70M	-38.36M	159.59M	119.47M
Investing Cash Flow	-219.32M	-220.46M	-137.98M	46.58M	-525.11M	-983.27M
Financing Cash Flow	123.43M	24.64M	-102.26M	-270.33M	353.22M	843.15M

Ardent Health Partners, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.16
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARDT, the sentiment is Positive. The current price of 13.16 is above the 20-day moving average (MA) of 12.56, above the 50-day MA of 12.35, and below the 200-day MA of 14.01, indicating a neutral trend. The MACD of 0.20 indicates Negative momentum. The RSI at 58.07 is Neutral, neither overbought nor oversold. The STOCH value of 45.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARDT.

Ardent Health Partners, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADUS	78 Outperform	$2.06B	24.67	8.54%	―	14.29%	7.85%
ARDT	72 Outperform	$1.84B	7.17	25.56%	―	10.03%	197.26%
ACHC	72 Outperform	$2.18B	15.58	4.62%	―	5.64%	―
ASTH	72 Outperform	$1.54B	59.71	3.50%	―	51.97%	-64.10%
SEM	71 Outperform	$1.61B	12.11	8.15%	1.95%	-16.10%	-48.97%
Sector *	51 Neutral	$7.92B	-0.43	-41.69%	2.21%	22.29%	-1.85%
AGL	40 Underperform	$501.45M	―	-60.64%	―	10.12%	-29.12%

Ardent Health Partners, Inc. Corporate Events

Ardent Health Announces Departure of Hospital Operations President

On June 16, 2025, Ardent Health, Inc. announced the immediate departure of David Schultz from his role as President of Hospital Operations. His exit is classified as a ‘Qualifying Termination’ under the company’s Executive Severance Plan, entitling him to severance benefits as outlined in the company’s proxy statement and previous filings.